CVE:KNE Kane Biotech (KNE) Stock Price, News & Analysis C$0.04 +0.01 (+12.50%) As of 11:09 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartHeadlinesInsider TradesBuy This Stock About Kane Biotech Stock (CVE:KNE) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Kane Biotech alerts:Sign Up Key Stats Today's RangeC$0.05▼C$0.0550-Day RangeC$0.04▼C$0.0552-Week RangeC$0.04▼C$0.15Volume10,000 shsAverage Volume77,241 shsMarket CapitalizationC$7.48 millionP/E RatioN/ADividend Yield3.08%Price TargetN/AConsensus RatingN/A Company Overview Kane Biotech Inc., a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops its products using coactiv+ technology, an antimicrobial wound gel platform; and DispersinB technology, a naturally occurring enzyme that cleaves the bacterial surface polysaccharide poly-b-1, 6-N-acetylglucosamine for treating wounds and otic infections. It offers revyve, an antimicrobial wound gel; and shampoos, shampoo bars, and scalp detoxifiers under the DermaKB brand. The company is also developing coactiv+ Antimicrobial Surgical Hydrogel for use in surgical/acute wounds; coactiv+ Antimicrobial Wound Rinse for use in acute and chronic wounds; coactiv+ Antimicrobial Wound Gel Spray for use in acute, chronic wounds, and first and second degree burns; and DispersinB Hydrogel for prosthetic joint infection. Kane Biotech Inc. was incorporated in 2001 and is based in Winnipeg, Canada. Read More Receive KNE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Kane Biotech and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. KNE Stock News HeadlinesKane Biotech Inc.: Kane Biotech Completes U.S. FDA 510(k) Submission for revyve Antimicrobial Wound CleanserSeptember 17, 2025 | finanznachrichten.deKane Biotech Completes U.S. FDA 510(k) Submission for revyve® Antimicrobial Wound CleanserSeptember 16, 2025 | financialpost.comFREVEALED: Something Big Happening Behind White House Doorswhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for yourself. Once you see what’s unfolding behind the scenes, you’ll understand why I rushed this interview and opportunity to you today.September 23 at 2:00 AM | Paradigm Press (Ad)Kane Biotech Completes Enrollment in U.S. Case Series Studies of its revyve® Antimicrobial Wound Gel and SpraySeptember 10, 2025 | financialpost.comFKane Biotech to Present revyve® Clinical Data at Symposium on Advanced Wound Care (SAWC) Fall ConferenceSeptember 4, 2025 | markets.businessinsider.comKane Biotech Inc.: Kane Biotech Announces Second Quarter 2025 Financial ResultsAugust 30, 2025 | finanznachrichten.deInsiders' CA$1.86m Investments In Red Following Kane Biotech's CA$825k Dip In Market ValueAugust 5, 2025 | finance.yahoo.comKane Biotech Showcases revyve™ Preclinical and Clinical Case Study Findings at North American Wound Care ConferencesJuly 31, 2025 | finance.yahoo.comSee More Headlines KNE Stock Analysis - Frequently Asked Questions How have KNE shares performed this year? Kane Biotech's stock was trading at C$0.11 on January 1st, 2025. Since then, KNE stock has decreased by 59.1% and is now trading at C$0.05. How do I buy shares of Kane Biotech? Shares of KNE stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers. What other stocks do shareholders of Kane Biotech own? Based on aggregate information from My MarketBeat watchlists, some other companies that Kane Biotech investors own include Mason Resources (LLG), Datametrex AI (DM) and Allstar Health Brands (ALST). Industry, Sector and Symbol Stock ExchangeCVE SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolCVE:KNE CIKN/A Webwww.kanebiotech.com Phone+1-204-4531301FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Trailing Twelve Months)C($0.09) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeC$6.03 million Net Margins423.52% Pretax MarginN/A Return on Equity-94.49% Return on Assets-58.43% Debt Debt-to-Equity Ratio-331.42 Current Ratio0.80 Quick Ratio0.39 Sales & Book Value Annual SalesC$1.85 million Price / Sales4.05 Cash FlowC$0.01 per share Price / Cash Flow8.50 Book ValueC($0.01) per share Price / Book-8.74Miscellaneous Outstanding Shares166,233,000Free FloatN/AMarket CapC$7.48 million OptionableNot Optionable Beta0.01 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for October 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free Report This page (CVE:KNE) was last updated on 9/23/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kane Biotech Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kane Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.